Linked Life Data

17076986

Source:http://linkedlifedata.com/resource/pubmed/id/17076986

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2006-11-1
pubmed:abstractText
Previous studies in Alzheimer's Disease (AD) suggest a benefit from switching from one cholinesterase (ChE) inhibitor to another in the event of treatment failure on the index agent. This observational, open-label study sought to evaluate the efficacy of the ChE inhibitor rivastigmine on cognition, functional autonomy and behavior in patients with mild-to-moderate AD previously treated with other ChE inhibitors (switched patients) as well as in those previously ChE-inhibitor-naive (de novo users).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1473-4877
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2251-65
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
pubmed:affiliation
McGill Centre for Studies in Aging, Douglas Hospital, Montreal, Quebec, Canada. serge.gauthier@mcgill.ca
pubmed:publicationType
Journal Article, Clinical Trial